Kalaris Therapeutics (NASDAQ:KLRS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kalaris Therapeutics (NASDAQ:KLRS) from a sell rating to a hold rating in a research note released on Saturday,Wall Street Zen reports.

Other analysts also recently issued reports about the company. Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a research note on Wednesday, May 13th. Citizens Jmp reduced their target price on Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. Weiss Ratings lowered shares of Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Wedbush assumed coverage on shares of Kalaris Therapeutics in a research note on Thursday, May 14th. They set an “outperform” rating and a $17.00 price target on the stock. Finally, TD Cowen assumed coverage on shares of Kalaris Therapeutics in a report on Monday, June 15th. They issued a “buy” rating for the company. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Kalaris Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $18.75.

Kalaris Therapeutics Price Performance

Shares of NASDAQ:KLRS opened at $3.90 on Friday. Kalaris Therapeutics has a 52 week low of $3.03 and a 52 week high of $11.88. The company has a 50-day moving average price of $4.12 and a 200 day moving average price of $5.55. The company has a market cap of $92.86 million, a P/E ratio of -1.93 and a beta of 0.22.

Kalaris Therapeutics (NASDAQ:KLRS) last released its earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.02. Analysts expect that Kalaris Therapeutics will post -1.99 EPS for the current year.

Institutional Trading of Kalaris Therapeutics

A number of institutional investors have recently bought and sold shares of KLRS. RTW Investments LP acquired a new stake in Kalaris Therapeutics in the fourth quarter valued at $10,972,000. Paradigm Biocapital Advisors LP acquired a new position in shares of Kalaris Therapeutics during the 4th quarter worth $5,908,000. Alyeska Investment Group L.P. purchased a new stake in shares of Kalaris Therapeutics in the 4th quarter worth about $3,402,000. Ikarian Capital LLC purchased a new stake in shares of Kalaris Therapeutics in the 4th quarter worth about $3,038,000. Finally, Woodline Partners LP acquired a new stake in Kalaris Therapeutics in the 3rd quarter valued at about $1,394,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.